Follica, Inc. is developing novel therapies for the treatment of conditions and disorders associated with the hair follicle, the “master” control center for the development and replenishment of human hair and skin.
Treatments for conditions of the follicle, primarily hair loss, acne, and pigmentation issues, account for a total market exceeding $10 billion annually, despite a lack of truly effective solutions. Follica has assembled a world class team of scientific, clinical, and industry experts that will harness the recent advances in epithelial cell biology to identify and develop novel therapeutic approaches to these disorders.
Multiple forces are converging to create broad opportunities for new treatments of conditions of the follicle. In 2004 hair and acne investigators, including Follica advisors, published breakthrough work elucidating follicle biology [i,ii] . At the same time, consumers and physicians alike are embracing aesthetic medicine at an unprecedented rate: The number of U.S. aesthetic/cosmetic surgical procedures increased from 2.1 billion in 1999 to 8.3 billion in 2003 [iii], and last year patients spent $12 billion worldwide on cosmetic surgery and facial rejuvenation [iv]. Existing treatments for follicle disorders like hair loss and acne have issues with efficacy, safety, or both, and the development of new treatments has not kept pace with this increased appetite for aesthetic treatment.
More information - clinical testing
If you are interested in clinical testing if and when it is announced, please send an e-mail with your name and contact information to

i Morris et al.
Nature Biotech. 2004; 22:411-17.
ii Tumbar et al.
Science 2004 :303 :359-363.
iii American Academy of Aesthetic Plastic Surgery
iv Cosmetic Surgery News |